Grail Webinar

NEW MEMBER BENEFIT

Despite significant advances in therapy, cancer is still the second leading cause of death in the United States. The costs of treating cancer, including drugs, hospitalization, and ambulatory care, as well as lost productivity and absenteeism, exceed $257 billion annually.

Early detection is crucial to reducing these burdens, improving outcomes and quality of life by making it possible for therapy to begin sooner. Blood-based multi-cancer early detection (MCED) tests are available to screen asymptomatic individuals for dozens of cancer types.

Join our webinar to learn more about:

• The science behind MCED screening;
• How to incorporate MCED testing into primary care practice;
• Appropriate diagnostic follow-up in response to a positive test.

View Recording
PowerPoint
Upcoming Grail Events: 11/7/24 & 12/11/24

Additional publication resources:
https://grail.com/manuscripts/

1. Validation for current Galleri assay: Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set (All of our sensitivity, specificity test performance metrics are from this study)

2. Implementation study: Blood-based tests for multi cancer early detection (PATHFINDER): a prospective cohort study (Our 43% positive predictive value comes from this study)

3. Case series publication (Three stage 1 diagnoses): A multi-cancer early detection blood test using machine learning detects early-stage cancers lacking USPSTF-recommended screening.